Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
Want to see MIST full AI Analyst Report?
Total Valuation
Milestone Pharmaceuticals has a market cap or net worth of $174.30M. The enterprise value is $187.11M.
Market Cap$174.30M
Enterprise Value$187.11M
Share Statistics
Milestone Pharmaceuticals has 124,497,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding124,497,980
Owned by Insiders0.90%
Owned by Institutions11.92%
Financial Efficiency
Milestone Pharmaceuticals’s return on equity (ROE) is -1.51 and return on invested capital (ROIC) is -62.00%.
Return on Equity (ROE)-1.51
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-62.00%
Return on Capital Employed (ROCE)-0.63
Revenue Per Employee46.85K
Profits Per Employee-1.91M
Employee Count33
Asset Turnover0.01
Inventory Turnover0.18
Valuation Ratios
The current PE Ratio of Milestone Pharmaceuticals is ―. Milestone Pharmaceuticals’s PEG ratio is -0.23.
PE Ratio―
PS Ratio109.60
PB Ratio4.06
Price to Fair Value4.06
Price to FCF-3.43
Price to Operating Cash Flow-3.56
PEG Ratio-0.23
Income Statement
In the last 12 months, Milestone Pharmaceuticals had revenue of 1.55M and earned -63.06M in profits. Earnings per share was -0.75.
Revenue1.55M
Gross Profit1.43M
Operating Income-62.48M
Pretax Income-63.40M
Net Income-63.06M
EBITDA-62.14M
Earnings Per Share (EPS)-0.75
Cash Flow
In the last 12 months, operating cash flow was -51.21M and capital expenditures -68.98K, giving a free cash flow of -51.23M billion.
Operating Cash Flow-51.21M
Free Cash Flow-51.23M
Free Cash Flow per Share-0.41
Dividends & Yields
Milestone Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.69
52-Week Price Change-7.89%
50-Day Moving Average1.68
200-Day Moving Average1.90
Relative Strength Index (RSI)33.10
Average Volume (3m)1.60M
Important Dates
Milestone Pharmaceuticals upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Milestone Pharmaceuticals as a current ratio of 8.01, with Debt / Equity ratio of 380.95%
Current Ratio8.01
Quick Ratio7.96
Debt to Market Cap0.34
Net Debt to EBITDA0.24
Interest Coverage Ratio-16.28
Taxes
In the past 12 months, Milestone Pharmaceuticals has paid -345.00K in taxes.
Income Tax-345.00K
Effective Tax Rate<0.01
Enterprise Valuation
Milestone Pharmaceuticals EV to EBITDA ratio is -2.49, with an EV/FCF ratio of -3.14.
EV to Sales100.11
EV to EBITDA-2.49
EV to Free Cash Flow-3.14
EV to Operating Cash Flow-3.16
Balance Sheet
Milestone Pharmaceuticals has $184.22M in cash and marketable securities with $137.33M in debt, giving a net cash position of $46.89M billion.
Cash & Marketable Securities$184.22M
Total Debt$137.33M
Net Cash$46.89M
Net Cash Per Share$0.38
Tangible Book Value Per Share$0.50
Margins
Gross margin is 94.67%, with operating margin of -4041.72%, and net profit margin of -4078.78%.
Gross Margin94.67%
Operating Margin-4041.72%
Pretax Margin-4101.10%
Net Profit Margin-4078.78%
EBITDA Margin-4019.40%
EBIT Margin-4041.72%
Analyst Forecast
The average price target for Milestone Pharmaceuticals is $7.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.25
Price Target Upside245.24% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast17.64%